公开(公告)号：US20210252011A1

公开(公告)日：2021-08-19

申请号：US15733029

申请日：2018-10-25

Applicant: FORMA Therapeutics, Inc. ,  Cornell University

Inventor： Wei LU ,  Matthew W. MARTIN ,  Erik WILKER ,  Howard FINE

IPC: A61K31/55 ,  A61K31/496 ,  A61K9/00 ,  A61P35/00

Abstract: The present disclosure relates to methods of treating glioblastoma by administering to a patient in need thereof a FASN inhibitor.

公开(公告)号：US20240148718A1

公开(公告)日：2024-05-09

申请号：US18220779

申请日：2023-07-11

Applicant: FORMA Therapeutics, Inc.

Inventor： Susan ASHWELL ,  Blythe THOMSON ,  Patrick F. KELLY ,  Alan COLLIS ,  Jeff DAVIS ,  Duncan WALKER ,  Wei LU

IPC: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

CPC classification number: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US20170174658A1

公开(公告)日：2017-06-22

申请号：US15452256

申请日：2017-03-07

Applicant: Forma Therapeutics, Inc.

Inventor： Jian LIN ,  Anna ERICSSON ,  Ann-Marie CAMPBELL ,  Gary R. GUSTAFSON ,  Zhongguo WANG ,  R. Bruce DIEBOLD ,  Susan ASHWELL ,  David LANCIA, JR. ,  Justin Andrew CARAVELLA ,  Wei LU

IPC: C07D401/12 ,  C07D471/04 ,  C07D401/14

CPC classification number: C07D401/12 ,  A61K31/47 ,  A61P35/00 ,  C07D401/14 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US20210244727A1

公开(公告)日：2021-08-12

申请号：US17243177

申请日：2021-04-28

Applicant: FORMA Therapeutics, Inc.

Inventor： Susan ASHWELL ,  Blythe THOMSON ,  Patrick F. KELLY ,  Alan COLLIS ,  Jeff DAVIS ,  Duncan WALKER ,  Wei LU

IPC: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.